News

Technology News

Impax Pharma Completes Parkinson's Study Enrollment

Friday, April 16, 2010 5:14:00 AM PDT | VentureDeal Staff
Hayward, California  --  Impax Pharmaceuticals announced that it has completed enrollment of its Phase III trial of its late stage Parkinson's disease drug candidate.

The candidate, IPX066, is an investigational extended release carbidopa-levodopa product designed to achieve and sustain effective blood concentrations of levodopa.

This is the first of two Phase III studies that the company hopes to reveal results for an early 2011.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1